Does the Addition of an Oral β2 Agonist (Pirbuterol) to Long Term Oxygen Therapy Yield Further Benefit in Hypoxic Chronic Bronchitis and Emphysema?

Biernacki, W; Whyte, KF; Prince, K; MacNee, W; Flenley, DC

doi:10.1042/cs072054Pb

Article navigation

Conference Abstract| January 01 1987

Does the Addition of an Oral β₂ Agonist (Pirbuterol) to Long Term Oxygen Therapy Yield Further Benefit in Hypoxic Chronic Bronchitis and Emphysema?

W Biernacki

1Rayne Laboratory, Department of Respiratory Medicine, University of Edinburgh, City Hospital, Greenbank Drive, Edinburgh

Search for other works by this author on:

This Site

PubMed

Google Scholar

;

KF Whyte

1Rayne Laboratory, Department of Respiratory Medicine, University of Edinburgh, City Hospital, Greenbank Drive, Edinburgh

Search for other works by this author on:

This Site

PubMed

Google Scholar

;

K Prince

1Rayne Laboratory, Department of Respiratory Medicine, University of Edinburgh, City Hospital, Greenbank Drive, Edinburgh

Search for other works by this author on:

This Site

PubMed

Google Scholar

;

W MacNee

1Rayne Laboratory, Department of Respiratory Medicine, University of Edinburgh, City Hospital, Greenbank Drive, Edinburgh

Search for other works by this author on:

This Site

PubMed

Google Scholar

;

DC Flenley

1Rayne Laboratory, Department of Respiratory Medicine, University of Edinburgh, City Hospital, Greenbank Drive, Edinburgh

Search for other works by this author on:

This Site

PubMed

Google Scholar

Clin Sci (Lond) (1987) 72 (s16): 54P–55P.

https://doi.org/10.1042/cs072054Pb

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

Portland Press
5th Floor, 90 High Holborn,
London WC1V 6LJ

Portland Press Tel
+44 (0)20 3880 2795

Biochemical Society Tel
+44 (0)20 3880 2793
Email: editorial@portlandpress.com

Company no. 00892796
Registered Charity no. 253894
VAT no. GB 523 2392 69

Privacy and cookies
Accessibility

Does the Addition of an Oral β₂ Agonist (Pirbuterol) to Long Term Oxygen Therapy Yield Further Benefit in Hypoxic Chronic Bronchitis and Emphysema?

Article PDF first page preview

Article PDF first page preview

Cited By

Get Email Alerts

CONNECT

EXPLORE

Cover Image

Does the Addition of an Oral β2 Agonist (Pirbuterol) to Long Term Oxygen Therapy Yield Further Benefit in Hypoxic Chronic Bronchitis and Emphysema?

Article PDF first page preview

Article PDF first page preview

Sign in

Sign in to your personal account

Biochemical Society Member Sign in

Sign in via your Institution

Cited By

Get Email Alerts

Related Articles

CONNECT

EXPLORE

This Feature Is Available To Subscribers Only

Does the Addition of an Oral β₂ Agonist (Pirbuterol) to Long Term Oxygen Therapy Yield Further Benefit in Hypoxic Chronic Bronchitis and Emphysema?